Agility in Manufacturing Preparedness Act of 2023

Hozzl · 2023-12-15T16:05:23Z

Explore the details of Senate Bill 36 Agility in Manufacturing Preparedness Act of 2023 currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on Health. Stay informed on legislative developments.

12/15/2023, 4:05 PM

Summary of Bill S 36

Bill 118 s 36, also known as the Agility in Manufacturing Preparedness Act of 2023, is a piece of legislation introduced in the US Congress with the aim of enhancing the preparedness and agility of the manufacturing sector in the face of various challenges.

The bill focuses on several key areas to achieve its goals. Firstly, it seeks to promote innovation and technological advancements in manufacturing by providing funding and resources for research and development. This includes supporting the adoption of new technologies such as automation, artificial intelligence, and advanced manufacturing techniques.

Secondly, the bill aims to strengthen the supply chain resilience of the manufacturing sector. This involves improving coordination and communication between manufacturers, suppliers, and government agencies to better respond to disruptions and emergencies. Additionally, the bill emphasizes the importance of workforce development in the manufacturing sector. It calls for increased training and education programs to ensure that workers have the skills and knowledge needed to thrive in a rapidly evolving industry. Overall, the Agility in Manufacturing Preparedness Act of 2023 is a comprehensive piece of legislation that seeks to bolster the competitiveness and resilience of the US manufacturing sector through innovation, supply chain resilience, and workforce development.

Congressional Summary of S 36

Agility in Manufacturing Preparedness Act of 2023

This bill requires the Department of Health and Human Services (HHS) to seek to contract with the National Institute for Innovation in Manufacturing Biopharmaceuticals to assess and make recommendations concerning U.S. capabilities for biopharmaceutical manufacturing and related matters. HHS must coordinate with the Biomedical Advanced Research and Development Authority on this contract.

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill S 36

Bill S 36 is currently in the status of Bill Introduced since January 24, 2023. Bill S 36 was introduced during Congress 118 and was introduced to the Senate on January 24, 2023. Bill S 36's most recent activity was Read twice and referred to the Committee on Health, Education, Labor, and Pensions. as of January 24, 2023

Bipartisan Support of Bill S 36

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill S 36

Primary Policy Focus

Health

Potential Impact Areas

- Government studies and investigations

- Manufacturing

- Medical research

- Prescription drugs

- Research administration and funding

- Technology assessment

Alternate Title(s) of Bill S 36

Agility in Manufacturing Preparedness Act of 2023

A bill to review domestic biopharmaceutical manufacturing capabilities in order to improve public health and medical preparedness and response capabilities and domestic biopharmaceutical manufacturing capabilities.